LightPath™ Imaging System | Sagentia Innovation

LightPath™ Imaging System: Lightpoint Medical


The first approved low light imaging and
nuclear physics for intra-operative imaging
of cancer.

The LightPath™ Imaging System is a molecular imaging technology that has
the potential to detect cancer in real-time during surgery. The technology was
designed for patients with invasive breast cancer or ductal carcinoma in situ
undergoing wide local excision surgery, or men with high risk non-metastatic
prostate cancer undergoing a radical prostatectomy. It is used intra-operatively
to generate optical images of the uptake of positron emission tomography (PET)
imaging agents to help differentiate between tissue affected or unaffected by
cancer, which may be helpful in assessing surgical margins.

Our client asked:

Lightpoint’s vision conceived moving existing PET
radiopharmaceuticals from diagnostics to intraoperative imaging and
pathology with the LightPath™ Imaging System.

The project story:

Although the science behind the LightPath™ system has been known
for many years, this is the first time that it’s been utilised in this way.

The Sagentia Innovation team began by modelling relative
performance of approaches. We performed early proof-of-principle
demonstrations which informed later design.

To assure good system usability we collaborated with medical
research teams for in-vitro testing and proposed commercially viable
solutions for the operating theatre and pathology lab.

Haven't found what you were looking for?

Our marketsarrow pointing rightarrow pointing right

Our consultants, scientists and engineers redefine what’s possible and help R&D groups across the medical, industrial, consumer and food and beverage sectors achieve commercial return from their opportunities.

Our projectsarrow pointing rightarrow pointing right

We have completed over 10,000 projects for start-ups and global market leaders alike, from understanding the market & technology landscape through to developing and delivering complex products.

Get in touch